Citius Oncology, Inc. (CTOR) Net Margin
- 2026-06-30: Net Margin -597.40%.
- 2026-03-31: Net Margin -1595.98%.
- 2025-12-31: Net Margin -140.31%.
Complete source-backed net margin history.
- Available history
- 2025-12-31 to 2026-06-30
- Data captured
Historical Net Margin
| Date | Net Margin |
|---|---|
| 2026-06-30 | -597.40% |
| 2026-03-31 | -1595.98% |
| 2025-12-31 | -140.31% |
Annual Net Margin
| Date | Net Margin |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |